<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662710</url>
  </required_header>
  <id_info>
    <org_study_id>7902-015</org_study_id>
    <secondary_id>2020-001990-53</secondary_id>
    <secondary_id>MK-7902-015</secondary_id>
    <secondary_id>E7080-G000-321</secondary_id>
    <secondary_id>jRCT2051200127</secondary_id>
    <nct_id>NCT04662710</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)</brief_title>
  <acronym>LEAP-015</acronym>
  <official_title>Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902)&#xD;
      plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in&#xD;
      participants with advanced/metastatic gastroesophageal cancer.&#xD;
&#xD;
      The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is&#xD;
      superior to chemotherapy alone for both overall survival (OS) and progression-free survival&#xD;
      (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed&#xD;
      by blinded independent central review (BICR), in participants with programmed cell&#xD;
      death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 2 parts to the study: a Safety Run-in (Part 1) and the Main Study (Part 2). In&#xD;
      Part 1 (Safety Run-in), approximately 12 participants will be treated with lenvatinib in&#xD;
      combination with pembrolizumab and chemotherapy with either capecitabine and oxaliplatin&#xD;
      (CAPOX), or 5-fluorouracil (5-FU), Leucovorin, and oxaliplatin (mFOLFOX6). Participants will&#xD;
      be closely followed for dose-limiting toxicities for 21 days after the first dose of study&#xD;
      intervention.&#xD;
&#xD;
      In Part 2, up to 778 eligible participants (not including those participating in Part 1) will&#xD;
      be randomly assigned in a 1:1 ratio to either lenvatinib plus pembrolizumab plus chemotherapy&#xD;
      (CAPOX or mFOLFOX6) or Chemotherapy alone (CAPOX or mFOLFOX6).&#xD;
&#xD;
      Participants can receive up to 18 infusions (up to 2 years) of pembrolizumab in the first&#xD;
      course. Participants may be eligible to receive a second course of pembrolizumab&#xD;
      (approximately 1 year) at the investigator's discretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to ~21 days</time_frame>
    <description>Hematologic DLTs were defined as Grade 4 neutropenia lasting for ≥7 days, Grade 3 or Grade 4 febrile neutropenia, Grade 3 thrombocytopenia with bleeding, Grade 4 thrombocytopenia, or Grade 4 anemia. Other nonhematologic toxicities considered a DLT included any other Grade 4 or Grade 5 toxicity, Grade 3 toxicities lasting &gt;3 days (excluding nausea, vomiting, and diarrhea controlled by medical intervention within 72 hours, and Grade 3 rash in the absence of desquamation with no mucosal involvement), Grade 3 hypertension not able to be controlled by medication, ≥Grade 3 gastrointestinal perforation, ≥Grade 3 wound dehiscence requiring medical or surgical intervention, or any grade thromboembolic event. The number of participants in Part 1 with DLTs will be reported by treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to ~25 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 1 with AEs will be reported by treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to ~22 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 1 that discontinued study due to an AE will be reported by treatment arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Overall Survival (OS) in Participants with Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1</measure>
    <time_frame>Up to ~38 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause. OS will be reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: OS in All Participants</measure>
    <time_frame>Up to ~38 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause. OS will be reported by treatment arm for all participants in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants with PD-L1 CPS ≥1</measure>
    <time_frame>Up to ~28 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS will be reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All Participants</measure>
    <time_frame>Up to ~28 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented PD per RECIST 1.1 by BICR or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS will be reported by treatment arm for all participants in Part 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR in Participants with PD-L1 CPS ≥1</measure>
    <time_frame>Up to ~22 months</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and assessed by BICR. ORR will be reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: ORR Per RECIST 1.1 as Assessed by BICR in All Participants</measure>
    <time_frame>Up to ~22 months</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and assessed by BICR. ORR will be reported by treatment arm for all participants in Part 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Participants with PD-L1 CPS ≥1</measure>
    <time_frame>Up to ~22 months</time_frame>
    <description>For participants who demonstrated confirmed CR or PR, DOR is defined as the time from the first CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) to subsequent PD or death due to any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR will be reported by treatment arm for PD-L1 CPS ≥1 participants in Part 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: DOR Per RECIST 1.1 as Assessed by BICR in All Participants</measure>
    <time_frame>Up to ~22 months</time_frame>
    <description>For participants who demonstrated confirmed CR or PR, DOR is defined as the time from the first CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) to subsequent PD or death due to any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR will be reported by treatment arm for all participants in Part 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants with AEs</measure>
    <time_frame>Up to ~25 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 2 with AEs will be reported by treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to ~22 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in Part 2 that discontinued study due to an AE will be reported by treatment arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">790</enrollment>
  <condition>Advanced/Metastatic Gastroesophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Lenvatinib + Pembrolizumab + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive lenvatinib administered orally (PO) every day (QD) in combination with pembrolizumab intravenously (IV) every 6 weeks (Q6W) plus chemotherapy with either capecitabine and oxaliplatin (CAPOX) or chemotherapy with 5-FU, leucovorin, and oxaliplatin (mFOLFOX6). Induction with lenvatinib 8 mg QD plus pembrolizumab (400 mg Q6W) plus chemotherapy (CAPOX or mFOLFOX6) will be administered for 2 cycles (approximately 12 weeks), followed by consolidation with lenvatinib 20 mg QD plus pembrolizumab (400 mg Q6W) for 16 cycles. A cycle is 6 weeks (42 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive chemotherapy with either CAPOX Q3W or mFOLFOX6 Q2W. A cycle is 6 weeks (42 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>400 mg Q6W by IV infusion</description>
    <arm_group_label>Lenvatinib + Pembrolizumab + Chemotherapy</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Administered PO QD, 8 mg induction/20 mg consolidation.</description>
    <arm_group_label>Lenvatinib + Pembrolizumab + Chemotherapy</arm_group_label>
    <other_name>MK-7902</other_name>
    <other_name>E7080</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Lenvatinib + Pembrolizumab + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Lenvatinib + Pembrolizumab + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin (or Levoleucovorin)</intervention_name>
    <description>Administered by IV infusion at 400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Lenvatinib + Pembrolizumab + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m^2 bolus IV infusion followed by 2400 mg/m^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Lenvatinib + Pembrolizumab + Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has histologically and/or cytologically confirmed diagnosis of previously untreated,&#xD;
             locally advanced unresectable or metastatic gastroesophageal adenocarcinoma&#xD;
&#xD;
          -  Is not expected to require tumor resection during the treatment course&#xD;
&#xD;
          -  Has gastroesophageal adenocarcinoma that is not HER-2/neu positive&#xD;
&#xD;
          -  Has measurable disease as defined by RECIST 1.1 by scan with IV contrast as determined&#xD;
             by the local site investigator&#xD;
&#xD;
          -  Male participants agree to refrain from donating sperm and agree to either remain&#xD;
             abstinent from heterosexual intercourse as their preferred and usual lifestyle OR&#xD;
             agree to use contraception, during the intervention period and for ≥7 days after last&#xD;
             dose of lenvatinib or 90 days after last dose of chemotherapy-whichever comes last&#xD;
&#xD;
          -  Female participants not pregnant or breastfeeding are eligible to participate if not a&#xD;
             women of childbearing potential (WOCBP), or if a WOCBP they either use a contraceptive&#xD;
             method that is highly effective OR remain abstinent from heterosexual intercourse as&#xD;
             their preferred and usual lifestyle, and do not donate eggs (ova, oocytes) to others&#xD;
             or freeze/store for their own use, during the intervention period through 120 days&#xD;
             after last dose of pembrolizumab, 30 days after last dose of lenvatinib, or 180 days&#xD;
             after last dose of chemotherapy-whichever occurs last&#xD;
&#xD;
          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Scale within 3 days prior to the first dose of study treatment&#xD;
&#xD;
          -  Has adequately controlled blood pressure with or without antihypertensive medications&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has had previous therapy for locally advanced unresectable or metastatic&#xD;
             gastric/gastroesophageal junction (GEJ) esophageal adenocarcinoma&#xD;
&#xD;
          -  Has had major surgery within 28 days prior to first dose of study interventions&#xD;
&#xD;
          -  Has had radiotherapy within 14 days of randomization&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 5 years&#xD;
&#xD;
          -  Has known CNS metastases and/or carcinomatous meningitis&#xD;
&#xD;
          -  Has severe hypersensitivity (≥Grade 3) to treatment with an monoclonal antibody (mAb)&#xD;
             or known sensitivity or intolerance to any component of lenvatinib, pembrolizumab,&#xD;
             study chemotherapy agents and/or to any excipients, murine proteins, or platinum&#xD;
             containing products&#xD;
&#xD;
          -  Has had an allogeneic tissue/solid organ transplant&#xD;
&#xD;
          -  Has perforation risks or significant gastrointestinal (GI) bleeding&#xD;
&#xD;
          -  Has GI obstruction, poor oral intake (CAPOX participants), or difficulty in taking&#xD;
             oral medication (CAPOX participants)&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with&#xD;
             an agent directed to another stimulatory or coinhibitory T-cell receptor&#xD;
&#xD;
          -  Has received prior therapy with anti- vascular endothelial growth factor (VEGF)&#xD;
             tyrosine kinase inhibitor or anti-VEGF mAb&#xD;
&#xD;
          -  Has received a live or live-attenuated vaccine within 30 days before the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs)&#xD;
&#xD;
          -  Has radiographic evidence of encasement or invasion of a major blood vessel, or of&#xD;
             intratumoral cavitation&#xD;
&#xD;
          -  Has inadequate cardiac function&#xD;
&#xD;
          -  Has a history of (noninfectious) pneumonitis/interstitial lung disease that required&#xD;
             steroids or has current pneumonitis/interstitial lung disease&#xD;
&#xD;
          -  Has poorly controlled diarrhea&#xD;
&#xD;
          -  Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or&#xD;
             diuretic drugs within 2 weeks prior to enrollment.&#xD;
&#xD;
          -  Has peripheral neuropathy ≥Grade 2&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) or HIV 1/2 antibodies&#xD;
&#xD;
          -  Has a known history of hepatitis B (defined as HBsAg reactive) or known active&#xD;
             hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection&#xD;
&#xD;
          -  Has weight loss of &gt;20% within the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Medical Center ( Site 0009)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-444-2223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center ( Site 0017)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-562-4370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University ( Site 0052)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-550-5358</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Medical Center ( Site 0020)</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>508-856-3216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System ( Site 0023)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-2600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine ( Site 0027)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-6268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0202)</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541146834557</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman ( Site 0210)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>541148277000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEMIC ( Site 0209)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541152991580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Privado de Cordoba ( Site 0204)</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543514688846</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital ( Site 2305)</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61247343500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital ( Site 2307)</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+610242286200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women s Hospital ( Site 2304)</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61736463792</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hollywood Private Hospital-Medical Oncology ( Site 2308)</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61893891437</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur Site de Godinne ( Site 1005)</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3281423858</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent ( Site 1002)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293322371</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Delta ( Site 1006)</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3251237215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre ( Site 0101)</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>9024736054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - Juravinski Site ( Site 0106)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>905-387-9495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>819346111016216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Investigación del Cáncer James Lind ( Site 0414)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4780000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5694423272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IC La Serena Research ( Site 0410)</name>
      <address>
        <city>La Serena</city>
        <state>Coquimbo</state>
        <zip>1720430</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56953360057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Catolica del Maule ( Site 0411)</name>
      <address>
        <city>Talca</city>
        <state>Maule</state>
        <zip>3460000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56981340385</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez FALP ( Site 0403)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7500836</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56992108354</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica San Carlos de Apoquindo Red Salud UC Christus ( Site 0407)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7550000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56991612199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradfordhill ( Site 0404)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56998744662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital ( Site 2415)</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0551-62283666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital ( Site 2453)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86 88196340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>900 Hospital of the Joint ( Site 2409)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0591-22859663</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Xiamen University ( Site 2421)</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>(0592)2292201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital ( Site 2456)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>020-62786845</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital Of Hainan Medical University-Cancer rehabilitation and palliative treatment</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613707599070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital ( Site 2429)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>02787670138</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital ( Site 2440)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>073188651669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital ( Site 2419)</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8602583106666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tang Du Hospital ( Site 2432)</name>
      <address>
        <city>XI An</city>
        <state>Shaanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>18629190366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LinYi Cancer Hospital-Gastrology department ( Site 2463)</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86 13869908100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital ( Site 2424)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862136126309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital ( Site 2455)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862138804518</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital ( Site 2447)</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>18622221230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2428)</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0991-7819430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University ( Site 2414)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86057156731277</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital ( Site 2412)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613605716662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 0502)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3008457696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0508)</name>
      <address>
        <city>Valledupar</city>
        <state>Cesar</state>
        <zip>200001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>575 5602310 Ext. 305</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Cancerologico de Narino Ltda ( Site 0504)</name>
      <address>
        <city>Pasto</city>
        <state>Narino</state>
        <zip>520001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3155621316</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse ( Site 1107)</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33231455016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc ( Site 1106)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>03 45 34 80 68</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque ( Site 1110)</name>
      <address>
        <city>Pessac</city>
        <state>Gironde</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois ( Site 1117)</name>
      <address>
        <city>Epagny Metz-Tessy</city>
        <state>Haute-Savoie</state>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33450636605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu Nantes ( Site 1101)</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33244768398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot ( Site 1116)</name>
      <address>
        <city>Lyon</city>
        <state>Rhone-Alpes</state>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33472119692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor ( Site 1105)</name>
      <address>
        <city>Creteil</city>
        <state>Val-de-Marne</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33149812567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer Avignon-Provence ( Site 1103)</name>
      <address>
        <city>Avignon</city>
        <state>Vaucluse</state>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33490276268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis ( Site 1100)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142499597</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Saint Antoine ( Site 1102)</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33171975088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar der TU Muenchen ( Site 1200)</name>
      <address>
        <city>Muechen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+498941409696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest ( Site 1205)</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496976014187</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig ( Site 1211)</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493419712560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Berlin Campus Virchow-Klinikum ( Site 1202)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4930450653193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Facharztzentrum Eppendorf ( Site 1201)</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4940360352241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Privada Dr Rixci Ramirez Fallas ( Site 0702)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50230635474</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologika S.A. ( Site 0704)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222790939</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica ( Site 0701)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222781269</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soluciones Gastrointestinales S.A. ( Site 0706)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50240433708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Nuestra Senora del Pilar ( Site 0705)</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50258190718</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medi-K Cayala ( Site 0700)</name>
      <address>
        <city>Guatemala</city>
        <zip>01016</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50255505555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital ( Site 2503)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85235051042</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital. ( Site 2502)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85229902393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital ( Site 2501)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85222555034</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital ( Site 1402)</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 9</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0035318092010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center ( Site 1503)</name>
      <address>
        <city>Hadera</city>
        <zip>3810004</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247776745</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 1502)</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247771258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Medical Center ( Site 1501)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226777957</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center ( Site 1504)</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>4428132</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97297472337</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 1506)</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972522902160</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 1500)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 1608)</name>
      <address>
        <city>Meldola</city>
        <state>Abruzzo</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39 0543739423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1610)</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902882</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital ( Site 1600)</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390282244080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AULSS8 Berica-Ospedale S.Bortolo ( Site 1607)</name>
      <address>
        <city>Vicenza</city>
        <state>Veneto</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390444753606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele di Milano ( Site 1603)</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390226437624</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Universita degli Studi della Campania-Luigi Vanvitelli ( Site 1604)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390815666713</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Universitario Santa Maria della Misericordia ( Site 1609)</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390432559304</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 2601)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-4-7133-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center ( Site 2610)</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-89-999-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center ( Site 2621)</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-78-929-1151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital ( Site 2606)</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-78-302-4321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ibaraki Prefectural Central Hospital ( Site 2618)</name>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-296-77-1121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital ( Site 2611)</name>
      <address>
        <city>Kita-gun</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-87-898-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center ( Site 2608)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-520-2222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital ( Site 2600)</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-72-366-0221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center ( Site 2604)</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-48-722-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center ( Site 2609)</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-541-3231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital ( Site 2612)</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-82-221-2291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 2607)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6945-1181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 2602)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3542-2511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 2605)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3520-0111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital ( Site 2806)</name>
      <address>
        <city>Anyang-si</city>
        <state>Kyonggi-do</state>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82313804167</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 2804)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-31-787-8214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 2802)</name>
      <address>
        <city>Songpagu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82230103230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konyang University ( Site 2807)</name>
      <address>
        <city>Daejeon</city>
        <state>Taejon-Kwangyokshi</state>
        <zip>35365</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+821091372641</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 2803)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-2072-7616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 2800)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82222288132</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital ( Site 2805)</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220191237</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 2801)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-3410-6820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital ( Site 2808)</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82226263060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dolnoslaskie Centrum Onkologii. ( Site 1712)</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48713689483</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1704)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-034</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48506159219</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1702)</name>
      <address>
        <city>Przemysl</city>
        <state>Podkarpackie</state>
        <zip>37-700</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48661957237</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska KOMED ( Site 1701)</name>
      <address>
        <city>Konin</city>
        <state>Wielkopolskie</state>
        <zip>62-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48632428009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 1703)</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-780</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48606228277</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1816)</name>
      <address>
        <city>Chelyabinsk</city>
        <state>Chelyabinskaya Oblast</state>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79127949047</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical and Surgical Center n.a.N.I.Pirogov ( Site 1805)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74956037217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital with Polyclinic ( Site 1801)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79031691379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University REAVIZ ( Site 1814)</name>
      <address>
        <city>Samara</city>
        <state>Samarskaya Oblast</state>
        <zip>443011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79023785196</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Oncology Center ( Site 1810)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79052075653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General de Asturias ( Site 1901)</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34985106100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla ( Site 1902)</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34942202525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitari Vall d Hebron ( Site 1907)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932746085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Gregorio Maranon de Madrid ( Site 1904)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914269393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital ( Site 2903)</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886422052121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 2904)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 2901)</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886223123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation. Linkou ( Site 2902)</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>88633281200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sakarya Universitesi Tip Fakultesi ( Site 2007)</name>
      <address>
        <city>Sakarya</city>
        <state>Istanbul</state>
        <zip>54290</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902642956630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2003)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+9031259560009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Ankara Hastanesi ( Site 2004)</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903122536666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trakya Universitesi Tip Fakultesi ( Site 2000)</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902842357641</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ataturk Universitesi Tip Fakultesi Hastanesi ( Site 2005)</name>
      <address>
        <city>Erzurum</city>
        <zip>25240</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+904423446666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2002)</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902124143000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi ( Site 2001)</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323904387</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

